Emerging Science Session
|Event Time:||Tuesday April 25, 2017 5:45 pm to 7:15 pm|
|Topic(s):||Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Headache, Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG)|
|Description:||A special session emphasizing ongoing neuroscience research of an extraordinary nature, which warrants expedited presentation. Key aspects of the research must have taken place after October 24, 2016.|
Program Speakers - Tentative
|Currently there are no events in the timeline.|
|5:45 PM||001||A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial||
David Dodick, MD, FAAN
Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Allergan, Amgen, Alder, Dr Reddy’s, Merck, Dr Reddy’s, Promius, eNeura, Eli Lilly & Company, Insys therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, Boston Scientific, GBS, Colucid, Zosano, Laydenburg Thalmann, Biocentric, Biohaven, Magellan, Pfizer (Japan), Charleston Laboratories. Royalties: Oxford University Press and Cambridge University Press (Book Royalty). Uptodate – editorial/honoraria. CME companies honoraria/publishing honoraria/royalites: Chameleon Communications, Medscape, WebMD, Academy for Continued Healthcare Learning, Haymarket Medical Education, Miller Medical Communications, Global Scientific Communications, HealthLogix, Academy for Continued Healthcare Learning, Meeting LogiX, Health LogiX, . Dr. Dodick has received compensation for serving on the Board of Directors of . Dr. Dodick holds stock and/or stock options in Nocira, Second Opinion, .
|5:48 PM||002||Non-invasive Vagus Nerve Stimulation for the Acute Treatment of Episodic and Chronic Cluster Headache: Findings From the Randomized, Double-blind, Sham-Controlled ACT2 Study||
Peter Goadsby, MD, PhD
Dr. Goadsby has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Electrocore, Eli-Lilly, eNeura, Novartis, Teva. Dr. Goadsby has received personal compensation in an editorial capacity for Journal Watch, Up-to-Date, Oxford Univeristy Press, Massachusetts Medical Society, Walters Kluwer. Dr. Goadsby has received compensation for serving on the Board of Directors of Trigemina Inc. Dr. Goadsby has received research support from Amgen.
|5:51 PM||003||Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized medical treatment||
|5:54 PM||004||Intraputaminal AADC gene therapy for advanced Parkinson's disease: Interim Results of a Phase 1b Trial||
Chadwick Christine, MD
Research support from Voyager Therapeutics.
|5:57 PM||005||Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose Phase 2 study||
Mark Stacy, MD, FAAN
Consultation: Allergan, Avid, Best Doctors, Biotie, Eli Lilly, Lundbeck, Merz, Neuronova, Novartis Pharma (Japan), Osmotica, Pfizer, Saraepta Therapeutics, SK Life Sciences, Sunovion Pharmaceuticals, Inc. Advisory Boards: Benign Essential Blepharospasm . Editorial Board Member: Journal of Clinical Investigation (JCI). Informa Press for Handbook of Dystonia, Duke University for Wearing Off Questionnaire (WOQ). Grants: IMPAX, Pfizer, Pharma2B.
|6:00 PM||006||RESULTS OF A PHASE 1 STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN ALZHEIMER’S DISEASE AND PSP||
|6:03 PM||007||Sustained seizure reduction with adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC): Long-term results from the phase 3 EXIST-3 study||
David Franz, MD
I have received travel support and honoraria from Novartis. My employer has received payments for research studies conducted at CCHMC and for consulting work I have done from Novartis as well.. Support for other research at his institution from Novartis.
|6:06 PM||008||Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3)||
Anup Patel, MD
GW Pharmaceuticals and Liva Nova - Consulting Supernus - Scientific Advisory Board UCB Pharma - Scientific advisory board . GW Pharmaceuticals - Research Grant Upsher Smith - Research Grant Pediatric Epilepsy Research Foundation - Research Grant Brain Sentinel - Research Grant .
|6:09 PM||009||Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study||
Richard Finkel, MD
Grants and personal fees from Ionis Pharmaceuticals during ENDEAR and CHERISH; grants and advisor fees from Biogen, grants from Cytokinetics and advisor to Roche outside the submitted work; advisory capacity to non-profit organizations: the SMA Foundation, Cure SMA, SMA Reach (UK) and SMA Europe; serves on the Data Safety Monitoring Board for the AveXis gene transfer study... Grants and personal fees from Ionis Pharmaceuticals during ENDEAR, CHERISH; grants and advisor fees from Biogen, grants from Cytokinetics and advisor to Roche outside the submitted work; serves on the Data Safety Monitoring Board for the AveXis gene transfer study..
|6:12 PM||010||Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: the PATH Study||
Ivo Van Schaik, MD
Dr. van Schaik I.S. chairs a steering committee for CSL-Behring and received departmental honoraria for serving on scientific advisory boards for CSL-Behring, Baxalta and UCB. He received speakers fees from CSL-Behring and Kedrion. .
|6:15 PM||011||Results of a Phase 1b/2 Study of ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR1940-C-004)||
John Vissing, MD
I have served on Advisory boards of Alexion Pharmaceuticals and Ultragenyx.
|6:18 PM||012||Dual Responder Analyses of Both Muscle Strength and Activities of Daily Living, Eculizumab Versus Placebo, in Refractory Generalized Myasthenia Gravis (gMG) Patients: Results from the REGAIN Study||
James Howard, MD, FAAN
Pfizer - family and self own stock as part of an overall portfolio;Johnson & Johnson - family and self own stock as part of an overall portfolio;General Electric - family and self own;. Alexion Pharmaceuticals: Research grant support for clinical trial support, payable to the University of North Carolina..
|6:21 PM||013||Comparison of protein-coding and long, non-coding RNA gene expression signatures to classify multiple sclerosis||
Charles Spurlock, PhD
Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock is co-founder and CEO of IQuity, Inc. IQuity has licensed technology from Vanderbilt University Medical Center where Dr. Spurlock serves on the faculty. . Dr. Spurlock is co-founder and CEO of IQuity, Inc.. Dr. Spurlock has received research support at Vanderbilt University Medical Center from Pfizer to support basic science research. .
|6:24 PM||014||A ‘surface-in’ gradient of thalamic damage is an early and disease-specific process in pediatric-onset multiple sclerosis||
Giulia Fadda, MD
Dr. Fadda has nothing to disclose.
Saturday April 21, 2018
|7:00 AM-9:00 AM|
|C4||Hyperkinetic Movement Disorders: Videodiagnosis and Treatment||Steven Frucht MD|
|9:30 AM-11:30 AM|
|C9||Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies||Amanda Peltier MD, MS|
|C11||Treatment of Pediatric Multiple Sclerosis in the Current Era||Brenda Banwell MD, FAAN|
|C14||Parkinson's Disease Update||Melissa Nirenberg MD, PhD, FAAN|
|12:00 PM-4:00 PM|
|C16||Neurophysiologic Intraoperative Monitoring Skills Workshop (Registration Required)||Aatif Husain MD|
|1:30 PM-3:30 PM|
|C18||Pediatric Neuro-ophthalmology Update||Christopher Glisson DO|
|C20||Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia||Amanda Peltier MD, MS|
|C21||Stroke in Young Adults and Women||Aneesh Singhal MD, FAAN|
|C23||Diagnosis and Treatment of Functional Movement Disorders||Mark Hallett MD, FAAN|